Literature DB >> 1425815

Pharmacokinetics of mitomycin C in patients after bolus injection and chemobolisation of the hepatic artery with Spherex starch particles.

M J Czejka1, W Jäger, J Schüller.   

Abstract

The pharmacokinetics of mitomycin C after chemobolisation of the common hepatic artery by micronized Spherex starch particles (mean particle size 30 microns) were investigated in 5 cancer patients. Bolus injection and simultaneous occlusion of the artery lead to a significantly lower systemic circulation of mitomycin C in the blood vessel system than after bolus injection without chemobolisation. The plasma concentration-time curves showed lower values in the alpha-phase in the presence of Spherex (co = 743 ng/ml) than without starch particles (co = 987 ng/ml). Accordingly, the AUC values were significantly lower too (AUC = 28.6 micrograms/ml.h with Spherex and 39.7 micrograms/ml.h without Spherex), thus leading to a lower systemic bioavailability of the drug and a higher local bioavailability in the tumor region. Elimination of mitomycin from the central compartment was similar for both administrations (t1/2 = 27 min with Spherex and 28 min without Spherex) and showed the characteristic profile of the substance. The clinical picture showed a milder toxicity with a certain loss of side effects. These results indicate a significant and desirable change in the pharmacokinetics of mitomycin C during the distribution phase into the tissue of patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425815     DOI: 10.1007/BF03188775

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  4 in total

1.  Mitomycin C determination using loop-column extraction: a rapid and sensitive high-performance liquid chromatographic assay for pharmacokinetic studies with Spherex starch particles.

Authors:  M J Czejka; W Jäger; J Schüller
Journal:  J Chromatogr       Date:  1989-12-29

2.  Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

Authors:  R G Buice; H B Niell; P Sidhu; B J Gurley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Handling of biological samples in the determination of the anti-neoplastic drug mitomycin C.

Authors:  J den Hartigh; G Voortman; W J van Oort; H Weenen; H M Pinedo
Journal:  J Pharm Biomed Anal       Date:  1985       Impact factor: 3.935

4.  Pharmacokinetics of mitomycin C in rabbit and human.

Authors:  G A van Hazel; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.